Syndax Pharmaceuticals (SNDX) Institutional Ownership

Of the 200 institutional investors that purchased Syndax Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Soleus Capital Management L.P. ($1.91M), Elmind Capital LP ($1.86M), Assenagon Asset Management S.A. ($1.79M), Eventide Asset Management LLC ($1.27M), Vanguard Group Inc. ($1.20M), First Turn Management LLC ($1.19M), and Bank of America Corp DE ($967.87K).

Institutional investors have bought a total of 21,422,393 shares in the last 24 months. This purchase volume represents approximately $338.91M in transactions.

Of the 83 institutional investors that sold Syndax Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Assenagon Asset Management S.A. ($2.00M), Balyasny Asset Management L.P. ($1.69M), JPMorgan Chase & Co. ($870.98K), Sofinnova Investments Inc. ($750.78K), Granahan Investment Management LLC ($685.07K), Bank of America Corp DE ($602.03K), and Eversept Partners LP ($581.69K).

Institutional investors have sold a total of 13,841,070 shares in the last 24 months. This volume of shares sold represents approximately $220.65M in transactions.